This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
pharmaceuticals: Archive
Biogen Secures FDA Nod for Subcutaneous Maintenance Dosing of Leqembi
by Zacks Equity Research
BIIB wins FDA approval for Leqembi Iqlik, a fast, subcutaneous option for early Alzheimer's patients transitioning from IV infusions.
BIIBPositive Net Change LLYPositive Net Change ANIPNegative Net Change CRMDPositive Net Change
biotechs medical pharmaceuticals
The Zacks Analyst Blog Highlights Lilly, Oracle, Procter & Gamble and Comstock Holding Companies
by Zacks Equity Research
Zacks spotlights Eli Lilly, Oracle, Procter & Gamble, and microcap Comstock Holding, with pharma and staples facing pressure while Oracle and Comstock show momentum.
PGPositive Net Change LLYPositive Net Change ORCLNegative Net Change CHCIPositive Net Change
computers construction consumer-discretionary pharmaceuticals
Is ELV's Push Beyond Insurance a Blueprint for the Healthcare Future?
by Zacks Equity Research
Elevance Health expands beyond insurance into primary care, digital health and pharmacy services, aiming to reshape healthcare delivery.
UNHNegative Net Change HUMPositive Net Change ELVPositive Net Change
insurance medical pharmaceuticals
Boyd Gaming and Shoe Carnival have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Boyd Gaming surges on strong earnings and growth plans, while Shoe Carnival struggles with sliding sales and weaker momentum.
PFEPositive Net Change MRNANegative Net Change BYDPositive Net Change NVAXPositive Net Change SCVLNegative Net Change
consumer-discretionary medical pharmaceuticals retail
J&J Ends Imaavy Development in Rheumatoid Arthritis Post Study Failure
by Zacks Equity Research
JNJ halts Imaavy's rheumatoid arthritis program after trial results showed no added benefit over existing therapy.
JNJPositive Net Change ANIPNegative Net Change CRMDPositive Net Change
biotechs medical pharmaceuticals
OTLK Stock Crashes 54% as FDA Issues Second CRL for Eye Disease Drug
by Zacks Equity Research
Outlook Therapeutics stock plunges 54% after the FDA rejects ONS-5010 BLA again, citing lack of efficacy data in confirmatory study.
CRMDPositive Net Change KNSAPositive Net Change OTLKNegative Net Change PHARNegative Net Change
biotechnology biotechs medical pharmaceuticals
ABBV or MRK: Which Stock Should Investors Place Their Bet on in 2025?
by Kinjel Shah
AbbVie edges past Merck in 2025 as strong Skyrizi and Rinvoq sales, pipeline gains and rising estimates fuel growth momentum.
JNJPositive Net Change MRKPositive Net Change LLYPositive Net Change ABBVPositive Net Change
pharmaceuticals
Top Stock Reports for Eli Lilly, Oracle & Procter & Gamble
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly, Oracle, and Procter & Gamble, as well as a micro-cap stock, Comstock.
PGPositive Net Change LLYPositive Net Change UNPPositive Net Change CVSPositive Net Change ORCLNegative Net Change BKRPositive Net Change CHCIPositive Net Change
pharmaceuticals tech-stocks
MRK, Daiichi Begin Phase III Breast Cancer Study With ADC Candidate
by Zacks Equity Research
Merck and Daiichi Sankyo begin dosing in the phase III HERTHENA-Breast04 study on patritumab deruxtecan in certain breast cancer patients.
AZNPositive Net Change PFEPositive Net Change MRKPositive Net Change
pharmaceuticals
Can Alnylam Rely on Amvuttra to Sustain Its Rapid Sales Momentum?
by Ahan Chakraborty
ALNY's Amvuttra revenues surge with 89% sales growth in H1 and a key label expansion, but faces tough competition in the ATTR-CM market.
ALNYNegative Net Change PFEPositive Net Change BBIOPositive Net Change
biotechnology biotechs medical pharmaceuticals
INO Stock Soars as FDA Backs Rolling BLA for Rare Lung Disease Drug
by Zacks Equity Research
Inovio stock surges 21% after the FDA gives green light to begin a rolling BLA for its RRP drug INO-3107, with plans to seek priority review.
INOPositive Net Change CRMDPositive Net Change KNSAPositive Net Change PGENPositive Net Change
biotechnology biotechs medical pharmaceuticals
Can Pfizer's Cost Cuts and New Drugs Offset Upcoming Headwinds?
by Kinjel Shah
Pfizer braces for patent losses, IRA pressure and COVID uncertainty, but cost cuts and key drugs may still support profit growth.
JNJPositive Net Change PFEPositive Net Change MRKPositive Net Change LLYPositive Net Change
pharmaceuticals
Will Weak Gardasil Sales Continue to Be a Drag on MRK's Top Line?
by Kanishka Das
Merck halts Gardasil shipments in China after weak demand hurts sales, with declines also seen in Japan.
SNYPositive Net Change AZNPositive Net Change MRKPositive Net Change
pharmaceuticals
CRSP vs. BEAM: Which Gene Editing Stock Holds More Potential Right Now?
by Sundeep Ganoria
CRISPR Therapeutics gains momentum with Casgevy sales and a broader pipeline, while Beam Therapeutics advances base-editing therapies still in early stages.
VRTXPositive Net Change BEAMNegative Net Change CRSPPositive Net Change
biotechs crispr gene-editing gene-therapy medical pharmaceuticals
What Is the Intent Behind AbbVie's Recent Acquisition Spree?
by Zacks Equity Research
ABBV's $1.2B neuroscience deal and 30+ acquisitions highlight its push to expand beyond immunology into obesity, oncology and brain health.
JNJPositive Net Change LLYPositive Net Change ABBVPositive Net Change
biotechs medical pharmaceuticals
Novo Nordisk vs. Viking Therapeutics: Which GLP-1 Stock is a Safer Bet?
by Ahan Chakraborty
NVO and VKTX face setbacks and rising competition as they battle for ground in the GLP-1 obesity market.
NVONegative Net Change LLYPositive Net Change VKTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Will Camzyos Strengthen BMY's Cardiovascular Portfolio?
by Ekta Bagri
Bristol Myers leans on Eliquis and surging Camzyos sales to offset looming generics, while its pipeline candidate milvexian readouts are near.
BMYPositive Net Change JNJPositive Net Change PFEPositive Net Change CYTKPositive Net Change
biotechnology biotechs medical pharmaceuticals
Does Lilly's New Obesity Pill Data Put It Back in the Weight Game?
by Kinjel Shah
LLY's obesity pill orforglipron hits weight-loss and A1C goals in a phase III trial, lifting shares nearly 6% and reviving investor confidence.
NVONegative Net Change LLYPositive Net Change AMGNPositive Net Change VKTXPositive Net Change
pharmaceuticals
LLY vs. PFE: Which Pharma Giant Is the Better Pick for Investors?
by Kinjel Shah
Pfizer's cost cuts, new products and cheaper valuation give it an edge over Eli Lilly despite LLY's strong GLP-1 momentum.
PFEPositive Net Change NVONegative Net Change LLYPositive Net Change
pharmaceuticals
Durable Goods Orders Decreased Less Than Expected
by Zacks Equity Research
Durable Goods Orders Decreased Less Than Expected
LLYPositive Net Change BMOPositive Net Change BNSPositive Net Change
finance medical pharmaceuticals
Catalyst Pharmaceuticals Settles Firdapse Patent Litigation With Lupin
by Zacks Equity Research
CPRX secures a key win as its Firdapse patent litigation settlement with Lupin shields U.S. sales from generic competition until 2035.
CPRXPositive Net Change CRMDPositive Net Change KNSAPositive Net Change PHARNegative Net Change
biotechnology biotechs medical pharmaceuticals
Can Novo Nordisk Offset GLP-1 Pressures With Rare Disease Wins?
by Ahan Chakraborty
NVO faces slowing GLP-1 momentum but leans on rare disease wins and new Wegovy approval to bolster growth.
NVONegative Net Change LLYPositive Net Change VKTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Pre-Markets in Red but Improving on New Data
by Mark Vickery
We appear to be bouncing around a bit more in recent trading days after a steadier level following August 2nd lows.
LLYPositive Net Change BMOPositive Net Change BNSPositive Net Change
banking earnings inflation interest-rate pharmaceuticals
GILD Wins Approval for Twice-Yearly HIV Prevention Shot in the EU
by Zacks Equity Research
Gilead secures EU approval for twice-yearly HIV prevention shot Yeytuo, backed by strong trial data and expanded market protection.
GSKPositive Net Change PFEPositive Net Change GILDPositive Net Change CVSPositive Net Change
biotechnology biotechs medical pharmaceuticals
Can Label Expansion of Cabometyx Fuel Further Growth for EXEL?
by Ekta Bagri
The FDA approval to expand Exelixis' Cabometyx into neuroendocrine tumors is witnessing encouraging uptake and boosting investor focus.
NVSPositive Net Change MRKPositive Net Change EXELPositive Net Change
biotechnology biotechs medical pharmaceuticals